

# W-Compound can be used as a Biomarker for Fetal Thyroid Function and a Potential Tool for Screening Congenital Hypothyroidism

Sing-Yung Wu <sup>1\*</sup>, Haibo Zhao <sup>1</sup>, Bi-Xin Xi <sup>2</sup>, Dong-Bao Chen <sup>3</sup>, and Maria E. Fucito, CNMT <sup>1</sup>

<sup>1</sup> Department of Research, Veteran Administration University of California Irvine Medical Center, Long Beach, CA 90822.

<sup>2</sup> Analytical Pharmacology Core Facility, City of Hope, Duarte, CA 91010..

<sup>3</sup> Department of Obstetrics and Gynecology, University of California Irvine, Irvine, CA 92697.

\*Corresponding Author: Sing-Yung Wu, M.D., Ph.D., Radiology and Research Service (151), VA-UCI Medical Center, Long Beach, CA 90822, USA.

Received Date: 16 June 2022 | Accepted Date: 24 June 2022 | Published DATE: 30 June 2022

**Citation:** Sing-Yung Wu, Haibo Zhao, Bi-Xin Xi, Dong-Bao Chen, and Maria E. Fucito. (2022). W-Compound can be used as a Biomarker for Fetal Thyroid Function and a Potential Tool for Screening Congenital Hypothyroidism. *J. Endocrinology and Disorders*. 6(3): DOI:10.31579/2640-1045/122

**Copyright:** © 2022 Sing-Yung Wu, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Abstract

Sulfoconjugation is the major pathway for thyroid hormone (TH) metabolism, converting T4 to inactive metabolites, T4S, rT3S, and T3S in fetus, via sulfotransferases (SULT) and type 3 deiodinase in gestation. Consistent with high production rate of T4S and rT3S, there are high serum sulfated iodothyronine analogs, including T4S, T3S, rT3S, and 3,3'-T2S (T2S), in ovine and human fetal and preterm infants. Fetal TH metabolic pathways predict T2S as the major TH metabolite in the fetus. Since maternal T2S appears to be quantitatively derived from fetal T3 (the active TH), the amount of T2S in the maternal compartment correlates with fetal thyroid function in sheep. In humans, maternal serum contains high levels of radioimmunoassayable T2S; however, it displays as a peak adjacent to but unidentical to synthetic T2S on HPLC and we named it the W-Compound. Levels of W-Compound increase during pregnancy and peak as high as 20-fold to that of nonpregnant women. Maternal serum levels of W-Compound significantly correlate with fetal T4 and W-compound concentrations but not maternal serum T4 in euthyroid or hyperthyroid women, showing a distinct difference between fetal and maternal in TH metabolism. Fetal T2S is actively transferred to the mother via placenta and the quantity of T2S or its metabolite (W-Compound) in maternal compartment reflects fetal thyroid function. Thus, maternal serum W-Compound may be a biomarker for monitoring fetal thyroid function *in utero*, although more investigations are needed to determine if it can be used as an alternative strategy for screening/managing congenital hypothyroidism due to dysregulated thyroid hormone metabolism.

**Key words:** congenital hypothyroidism; fetal thyroid function; W-Compound; biomarker; neonatal screening

## Introduction:

The current screening program for congenital hypothyroidism (CHT) has allowed early treatment of this disorder and clearly improving long term outcomes [1-4]. However, despite the systematic screening and treatment of CHT, mild brain damages do occur [5, 6]. Since thyroid hormone (TH) is involved early first trimester fetal brain development including the neuronal cells [7-9], it is expected that developmental neuronal defects cannot be totally reversed postnatally. In developing mammals including humans, a deficiency or excess of TH in the developing brain during the fetal and neonatal periods can lead to morphological and functional abnormalities. Cretin is a serious form of congenital hypothyroidism (CHT), deficiency in TH in the newborn. These neonates suffer from not only impaired neurological function, but also stunted growth and physical

deformities. This condition may occur in babies with a hypofunctioning thyroid gland. An estimated 15 to 20% of cases of CHT are inherited including gene mutations [1]. Many inherited cases are autosomal recessive but those with a mutation in the PAX8 gene or certain thyroid stimulating hormone receptor (TSHR) gene mutations have an autosomal dominant pattern of inheritance [3]. Other possible cause of fetal hypothyroidism is anti-thyroid medication treatment for maternal hyperthyroidism and lack of iodine during pregnancy. The incidence of babies born with CHT is 1 in 2,000 - 4,000 live birth in developed countries [3], representing a significant public health problem; this calls for more attention in better perinatal and neonatal care that needs new screening tools for fetal thyroid function and CHT. Our work in the sulfation pathway in mammalian fetal TH metabolism has obtained data that suggest the fetal-to-maternal transferred 3,3'-diiodothyronine sulfate

(T<sub>2</sub>S)-like metabolite (W-Compound) can be used as novel marker for fetal thyroid function (10-12). The measurement of this compound in maternal serum and urine may serve as new marker for fetal thyroid function during *in utero* development.

**Current neonatal screening of thyroid function and CHT**

Neonatal screening programs began detecting neonates with CHT over 45 years ago. At present, 38 million births yearly worldwide undergo screening for this disorder [3]. The screening program for CHT has allowed early treatment of this disorder and clearly improving long term outcomes [2-4]. However, despite the systematic screening and treatment of CHT, mild brain damages do occur [5, 6]. Since thyroid hormone (TH) is involved early first trimester fetal brain development including the proliferation, migration, and differentiation of neuronal cells [7-9], it is expected that developmental neuronal defects cannot be totally reversed postnatally. These irreversible changes can impact on child IQ, cognitive

and motor measures [2, 5, 13-16]. Children affected may present reduced socio-educational achievement [17, 18], greater risk of autistic trait [14], and more ADHD (attention-deficit/hyperactivity disorder) symptoms [19]. Recently, it has been found that higher preconception maternal iodine intakes are associated with higher child IQ [20], indicating intervention before or during pregnancy may help the future outcome of children.

Unfortunately, the incidence of CHT in the United States showed a trend of increasing from ~ 1:4100 in 1987 to ~ 1:2400 in 2002 [21]. Similar increases (Table 1) were also observed in Australia [22], Italy [23], and Ireland [24]. Furthermore, some infants display a delayed thyroid stimulating hormone (TSH) rise that missed by neonatal screening [25]. Recent studies suggest that delayed TSH rise may be more common and more severe than previously recognized [26].

Nations/Time	1980-1989	1990-1999	2000-2009	2010-2019	Note
U.S.A.	0.24		0.42		Ref. 21
(Western) Australia	0.17	0.35			Ref. 22
Italy		0.33	0.51		Ref. 23
Ireland	0.27	0.38	0.50	0.75	Ref. 24

**Table 1:** Incidence of congenital hypothyroidism (Per 1000 Live Births) in developed countries.

In addition, despite the U.S. being iodine sufficient for the general population, the U.S. dietary iodine intakes have decreased drastically since the 1970s, with deficiency reemerging in vulnerable groups such as women of reproductive age [26]. All these findings indicate that there is room for improvement in the current strategy with neonatal CHT screening. Further study of fetal thyroid hormone metabolism and function is warranted as these studies may provide alternative strategies for managing CHT to avert unwanted sequelae.

**What are the differences in thyroid hormone metabolism between fetus and adult?**


Our lab at University of California (Irvine) - Long Beach VA Medical Center, in collaboration with Professor D. A. Fisher at UCLA-Harbor

General Medical Center, has found in mammalian fetuses that sulfoconjugation is the major pathway for TH metabolism (Figure. 1) [10, 27, 28].

Before the onset of active synthesis and release of TH, iodothyronines detected in the fetus clearly are maternal origin [15, 29]. This period is approximately the first 17 gestational days (d) in rats, 50d in sheep, and 90d in humans (Table 2 and Figure. 1, the upper horizontal light dotted line). The proposed scheme for ovine fetal iodothyronine metabolism in late gestation (near term) depicts the production rates for sulfoconjugated TH analogs (shown as numbers in parentheses along the thick arrows in Figure. 1).

	Sheep	Human	Rat
<b>Length of Gestation</b>	150 d	280 d	21 d
<b>Species</b>	precocial	precocial	altricial
<b>Thyroid Function at birth</b>	mature (similar to humans)	mature	immature (2nd trimester to human)
<b>CNS Development at birth</b>	mature	intermediate	immature
<b>Placenta: type:</b>	epitheliochorial	haemomonochorial	haemotrichorial
<b>origin:</b>	maternal and fetal	fetal only	fetal only
<b>layers:</b>	6	3	4
<b>Placental permeability to TH (vs. human)</b>	less permeable	----	more permeable
<b>Animal model to study placenta in late gestation</b>	yes	----	no

**Table 2:** Comparison of sheep, rat and humans in the study of fetal-to -maternal transfer of iodothyronines in pregnancy.



**Figure 1:** Postulated metabolic pathways for ovine fetal thyroid hormones (10, 30). Heavy solid lines indicate pathways that are more active in fetuses than in adults; thin solid lines, pathways that are less active in fetuses. The upper horizontal light dotted line depicts  $T_4$  of maternal origin moving to the fetal compartment in the first trimester, before the fetal thyroid begins functioning. The blue line indicates the transfer of fetal  $T_3$ , through placenta D3 and ST to form  $T_2S$ , into maternal compartment. Other broken lines represent unconfirmed pathways. Numbers in parentheses indicate published production rates ( $\mu\text{g}/\text{kg}/\text{d}$ ). (D1, D2, and D3: type I, type II, and type III iodothyronine deiodinases; ST: iodothyronine sulfotransferases (SULT); LAO/AT: L-amino acid oxidase/aminotransferase; DiacS: sulfated 3,3'-diiodothyroacetic acid, TriacS sulfated 3,3',5-triiodothyroacetic acid).

A kinetic study using the steady state constant infusion method in sheep showed that the major pathways of TH metabolism in the fetus convert  $T_4$  to inactive metabolites,  $rT_3$ ,  $T_4S$ ,  $rT_3S$ , and  $T_3S$ , via sulfotransferase and D3 enzyme systems in late gestation [10, 27, 28]. The high production rate ( $\mu\text{g}/\text{kg}/\text{d}$ ) of  $T_4$  sulfate ( $T_4S$ ) (Figure. 1) reflects the active activity of the sulfation pathway in the fetus [27,28]. The  $rT_3S$  production rate likely represents both sulfation of  $rT_3$  and inner-ring deiodination of  $T_4S$ .

Consistent with the high production rate of  $T_4S$  and  $rT_3S$ , we have shown high serum concentrations of sulfated iodothyronine analogs in ovine and human fetal and preterm infant sera. These include  $T_4S$ ,  $T_3S$ ,  $rT_3S$ , and 3,3'- $T_2S$  ( $T_2S$ ) [27, 28, 31-40]. Elevated iodothyronine sulfoconjugates are also detectable in amphibians during metamorphosis [41].

Thus, in developing mammals, sulfoconjugation of iodothyronine is an important pathway, in particular, during late gestation when the hypophyseal-pituitary-thyroid system becomes more mature in precocial species including sheep and humans. As term approaches, fetal thyroid gland secretion increases progressively while the effects of TH in many peripheral tissues must be delayed to the postpartum period. D3 and SULTs may serve to moderate the circulating THs before parturition. In addition, the shunting of iodothyronine metabolites of fetal origin into maternal circulation, the fetal to maternal transfer, is also an important mechanism in keeping an optimal active TH level in the developmental fetus.

#### The most common maternal circulating iodothyronine metabolite of fetal origin (-- the fetal to maternal transfer).

Thyroid hormone (TH) plays an important role in early fetal neurological maturation. Iodothyronines detected in the fetus before the onset of fetal thyroid function is of maternal origin. The maternal-fetal transfer of TH and their metabolites are apparently a two-way street. The high gradient

between fetal and maternal serum concentrations of iodothyronine sulfates raises the possibility of significant fetal to maternal transfer of iodothyronine sulfoconjugates.

Sack et al. [42] reported that umbilical cord cutting, thus removing the lamb from placental D3 and transfer, triggers hypertriiodothyroninemia in the newborn lamb and that the postnatal  $T_3$  peak can be delayed until well after the TSH peak by delaying umbilical cord cutting. Santini et al. [43] reported that the placenta plays an important role in maintaining the low serum  $T_3$  in fetuses late in gestation. These findings suggest an important role of the placenta in fetal  $T_3$  metabolism, (Fig. 1, the blue line); it is possible that fetal-to-maternal transfer of the sulfated iodothyronines (via placenta) is one mechanism responsible for reducing serum  $T_3$  concentrations in the fetus. Increasing fetal-to-maternal transfer of iodothyronines occurs in late gestation.

The scheme shown in Fig. 1 also predicts 3,3'- $T_2S$  is the major thyroid hormone metabolite in the fetus. Intravenous infusion of radioiodine labeled  $T_3$  and  $T_4$  into near-term fetuses, demonstrated a rapid clearance of labeled  $T_3$  from fetal serum (disappearance  $T_{1/2}$  of 0.7 hours). Labeled  $T_2S$  was identified as the major fetal iodothyronine metabolite in maternal urine [34]. Fetal  $T_3$  undergoes rapid inner-ring monodeiodination to 3,3'- $T_2$  which is an excellent substrate for all known mammalian iodothyronine sulfotransferases [10]. The rapid sulfoconjugation of the hydroxyl group in the outer-ring of 3,3'- $T_2$  forms a hydrophilic sulfated  $T_2$  ( $T_2S$ ) with enhanced permeability through placental membranes, facilitating the transfer of THs to maternal compartments. The  $T_2S$  of fetal origin appears to be rapidly cleared from the maternal circulation via excretion in urine [44]. Fetal  $T_4$ , on the other hand, disappears from the fetal circulation at a slower rate; a fast phase ( $T_{1/2}=2.4$  hours) in the first 3 hours followed by a slow phase ( $T_{1/2}=17.5$  hours). The major metabolites in fetal circulation after infusion of  $^{125}\text{I}-T_4$  were  $rT_3$  and  $T_3$  as well as their sulfates,  $T_4S$ ,  $rT_3S$

and 3, 3'-T<sub>2</sub>S. Negligible amounts of T<sub>3</sub>S, roughly 0.7 – 1.2%, were also detected [44].


Similar to fetal T<sub>3</sub> infusion, the most abundant metabolite found in maternal urine following radioactive T<sub>4</sub> infusion is T<sub>2</sub>S. The T<sub>4</sub> infusion study also confirms previous data in ovine fetuses [34, 35], indicating that the production of active thyroid hormone (T<sub>3</sub>) is less than the production of inactive products, rT<sub>3</sub>, T<sub>2</sub>S, rT<sub>3</sub>S and T<sub>3</sub>S [44].

T<sub>3</sub> derived from T<sub>4</sub> formed in the fetal circulation is converted to T<sub>2</sub>S, which is then transferred to the maternal compartment for deiodination/excretion. Recently, we have found sulfated [<sup>125</sup>I]-T<sub>2</sub>S was readily detected in the maternal compartment as the major metabolite of T<sub>3</sub> following the perfusion of placenta with [<sup>125</sup>I]-T<sub>3</sub> in guinea pig (12), suggesting that placental deiodinase and sulfotransferase may play an important role in fetal T<sub>3</sub> homeostasis and in the fetal to maternal transfer of sulfated iodothyronine metabolites. This process would contribute to the low circulating T<sub>3</sub> levels in the fetus. Since T<sub>2</sub>S appears to be quantitatively derived from circulating T<sub>3</sub> (the active TH in the fetus), a significant increase or decrease in T<sub>2</sub>S in the maternal circulation would suggest hyper- or hypothyroidism in the fetus. In thyroidectomized sheep model, we found that 3,3'-T<sub>2</sub>S excretion in maternal urine reflects fetal thyroid function [45]. These data indicate clearly that maternal-fetal transfer of TH and its metabolites is a two-way street despite ovine placenta is less permeable as compared to rat and/or human (Table 2).


Furthermore, studies in rats have shown that 3,3'-T<sub>2</sub> stimulates mitochondrial respiration in various tissues [46]. It is possible that a tight regulation of T<sub>2</sub> concentration by sulfation and fetal-to-maternal transfer would have physiological value. Enhancing fetal-to-maternal transfer may protect the fetus from excessive mitochondrial thermogenesis stimulated by high fetal concentrations of T<sub>2</sub>. Another T<sub>2</sub>, i.e. 3,5-T<sub>2</sub>, was also shown to stimulate mitochondrial thermogenesis [46, 47]; however, its production rate is much lower in the fetus due to the inactive D1 (Figure 1).

#### **W-Compound, a T<sub>2</sub>S-immuno-crossreactive compound, ought to be considered as a fetal thyroid function marker.**

In humans, we have found high levels of radioimmunoassayable T<sub>2</sub>S in maternal serum [37, 39]; its levels increase with gestational age and peaked just prior to parturition. At delivery, a 20-fold increase in serum "T<sub>2</sub>S" is present compared to nonpregnant women (Figure 2) and "T<sub>2</sub>S" levels return to nonpregnant values in 7 to 10 days after delivery (Figure.3). Serum levels were measured by a T<sub>2</sub>S-specific radioimmunoassay (RIA) in 60 serum samples from newborns with hyperbilirubinemia, age 1 to 30 days. It is found that radioimmunoassayable T<sub>2</sub>S is cleared at similar rates in newborn as in postpartum maternal sera. This is consistent with the hypothesis that this "T<sub>2</sub>S" is produced in the placenta [46] (Figure 3).




**Figure 2:** Changes of Compound W at different gestation periods. Normal values of T<sub>2</sub>S-crossreactive material (compound W) in serum from pregnant women, nonpregnant women (NP), and newborns. Vertical bars are mean ± 1 SD. \* p < 0.05 cf. 3-7 weeks pregnancy.



**Figure 3:** Concentrations of T<sub>2</sub>S and W-compound in cord serum of newborns and W-compound levels in maternal serum samples at the time of deliver (D). The connected lines represent serial measurements in the same patients (n = 18). T<sub>2</sub>S concentrations also were measured in 14 nonpregnant women (NP) for comparison. The percent reduction of levels in newborn and maternal groups in semi-log plot in the Insert: black lines are newborns; red line is post-partum mother. The closed red squares in vertical bars represent the mean (±SEM) and (n) represent the total number of samples studied at each time period in a total of 35 patients.

On closer examination, the radioimmunoassayable “T<sub>2</sub>S” did not cochromatography with synthetic T<sub>2</sub>S by HPLC [39], (Figure 4). Over 40 known synthetic thyroid hormone analogs that were examined, none was found to be identical to the serum T<sub>2</sub>S-like material in pregnant women [49]. Thus, the name W-Compound was given. It is postulated that W-


Compound is a side-chain modification of T<sub>2</sub>S, which cross-reacts with T<sub>2</sub>S antibody but is slightly more hydrophobic than T<sub>2</sub>S. Consistent with being an analogue of iodothyronine, we found high level of iodine content in highly purified W-Compound preparation analyzed by a Triple Quadrupole ICP-MS (Inductively Coupled Plasma Mass Spectrum) [50].




**Figure 4:** Elution patterns of W-compound and T<sub>2</sub>S which were identified by a sensitive RIA. Samples were eluted from HPLC isocratically with a mixture of acetonitrile and 0.02 mol/L ammonium acetate, pH 4.0 (22:78 vol/vol).

In normal pregnancy, both maternal and fetal W-Compound levels increase progressively with a significant direct correlation ( $p < 0.001$ , in both mothers and fetuses) [51], (Figure 5). In addition, in 436 paired cord

and maternal sera obtained from women at delivery, there is a highly significant correlation between the concentrations of Compound W in newborn cord and maternal sera ( $p < 0.01$ ) [49], (Figure 6).



**Figure 5:** W-compound levels in 49 fetal and 64 maternal sera correlation with the weeks of gestation.



**Figure 6:** Levels of T<sub>2</sub>S-crossreactive material, W-compound, in paired maternal and cord serum at term. The solid line is the trend-line from lineal regression analysis for the correlation (n = 436, R = 0.686).

A significant positive correlation is also observed between fetal serum concentrations of W-Compound and fetal T<sub>4</sub> (p<0.003) and between maternal and fetal W-Compound concentrations (p<0.0001) [51], (Figure.

7). However, no significant correlations were observed between maternal serum W-Compound and maternal serum T<sub>4</sub> in euthyroid or hyperthyroid women. These data strongly suggest the fetal origin of W-Compound.




Figure 7: W-Compound levels in fetal serum correlation with serum fetal FT4 (n=29) and maternal W-compound (n=42).




Figure 8: Sulfated iodothyronine (or the equivalence in T<sub>2</sub>S) levels in arterial (A) and venous (V) cord serum. Horizontal bars indicate the mean. \* For conversion to nmol/L T<sub>2</sub>S, multiply by 0.0165; nmol/L T<sub>3</sub>S and rT<sub>3</sub>S, multiply by 0.0156; nmol/L T<sub>4</sub>S, multiply by 0.0148.

To further explore the possible origin of W-Compound, the serum concentrations of sulfated iodothyronines from cord arterial and venous blood samples were compared [49]. There were no significant differences between the mean T<sub>3</sub>S, T<sub>4</sub>S, or reverse-T<sub>3</sub>S concentrations of arterial and venous serum samples. However, the venous concentration of the T<sub>2</sub>S-equivalent material was higher than that in arterial blood in seven of the paired samples and lower in two. The mean “corrected” concentration of W-Compound in nine pairs of cord sera was found to be significantly higher in venous than arterial blood samples suggesting the fetal origin of W [49]. In addition, the mean of the maternal serum concentrations of T<sub>2</sub>S-reactive material was significantly lower than that of the paired cord serum concentrations. The rapid disappearance of W-Compound from maternal blood immediately after delivery supports this hypothesis [39], (Figure 3). A similar disappearance slope of serum W-Compound was also found in newborn infants [48], (Figure. 3, insert). These findings support the postulation that W-Compound is produced in placenta with iodothyronine precursor of fetal origin.

### The Measurement of W-Compound: a technical consideration.

The original method for the measurement of W-Compound involves the use of RIA which was developed by Wu et al. [39]. Radioimmunoassay, in general, is not convenient to most clinical laboratories due to the involvement of using a radioisotope I<sup>125</sup>.

In a recent study, we have applied a highly sensitive and rapid homogeneous time-resolved fluorescence immunoassay to establish an indirect competitive W-Compound quantitative detection method called AlphaLisa (ICW-AlphaLisa), to measure the levels of W-Compound in maternal serum during pregnancy [52]. We developed specific polyclonal antibodies against W-Compound [a 3,3'-diiodothyronine sulfate (T<sub>2</sub>S) immuno-crossreactive material] and established an ICW quantitative detection method using AlphaLISA. In this method, photosensitive particles (donor beads) were coated with purified W-Compound or T<sub>2</sub>S and rabbit anti- W-Compound antibody, followed by incubation with biotinylated goat anti-rabbit antibody. This constitutes a detection system with streptavidin-coated acceptor particle. We have optimized the test conditions and evaluated the detection performance. The sensitivity of the method was 5 pg/ml in a detection range of 5-10,000 pg/ml. The intra-assay coefficient of variation averages <10% with stable reproducibility. The ICW-AlphaLISA shows good stability and high sensitivity and can measure a wide range of W-compound levels in extracts of maternal serum samples. This may have clinical application to screen congenital hypothyroidism in utero [52].

Brominated flame retardants (BFRs) have been recently shown to disrupt TH homeostasis through multiple mechanisms (53), including inhibition of enzymes that regulate intracellular levels of THs, such as sulfotransferases (SULTs). As discussed in the present review, the placenta plays a critical role in expressing D3 and SULTs to prevent the developing fetuses from exposure to high level of active thyroid hormone T<sub>3</sub>, which are needed immediately after birth. The adverse effect of BFRs is concerning, given that disruption of TH regulation within the placenta could potentially harm the developing fetus [28, 29]. Iodothyronines and their sulfoconjugates in these studies were measured by liquid chromatography-tandem mass spectrometry (LC/MS-MS) [54, 55]. Even though the claim was made that this method was comparable to RIA, however, the sensitivities to detect for 3,3'-T<sub>2</sub> and T<sub>2</sub>S were difficult to judge. Nevertheless, the lowest concentrations of standards used to optimize and calibrate the LC/MS-MS varied between 1-10 ng/ml that was much higher than the serum levels of 3,3'-T<sub>2</sub> and T<sub>2</sub>S in physiological states [37, 53- 56].

### Conclusions

Sulfoconjugation is a major metabolic pathway for thyroid hormone in developing mammals. The significant rise of sulfated iodothyronines in

fetal compartments raises the possibilities that remarkable fetal to maternal transfer of the TH sulfoconjugates may occur throughout the second and third trimester in humans. This transfer may be a novel mechanism to maintain low T<sub>3</sub> states or regulate serum 3,3'-T<sub>2</sub>, a thermogenic hormone, that is important for normal tissue maturity. The possibility that the transferred iodothyronine sulfate, especially 3,3'-T<sub>2</sub>S and its metabolite, may serve as a biomarker of fetal thyroid function needs to be further explored. Because the placenta plays a critical role in expressing D<sub>3</sub> and SULTs to prevent the developing fetuses from exposure to high level of active thyroid hormone T<sub>3</sub>, which is needed immediately after birth. To this end, the non-isotopic method we developed [49] provides a very valuable means to facilitate future studies on W-Compound as a fetal thyroid function biomarker. Because disruption of TH regulation within the placenta could potentially harm the developing fetus [28], further studies are warranted to explore the possibility of the maternal serum or urine levels of W-Compound as a biomarker for BFR toxicity.

### Abbreviations:

**ADHD** : Attention Deficit/Hyperactivity Disorder

**BFR** : Brominated flame retardants

**CHT** : Congenital Hypothyroidism

**D1, D2, and D3:** Type I, Type II, And Type III Iodothyronine Deiodinase

**DiacS** : Sulfated 3,3'-Diiodothyroacetic Acid

**LAO/AT** : L-Amino Acid Oxidase/Aminotransferase

**SULT or ST** : Sulfotransferases

**T1, T2 and T3** : Mono-, Di-, and Tri-iodothyronine

**T4** : Thyroxine

**T4S, T3S, rT3S, T2S and T1S:** Sulfated T<sub>4</sub>, T<sub>3</sub>, rT<sub>3</sub>, T<sub>2</sub> and T<sub>1</sub>

**TH** : Thyroid Hormone

**TriacS** : Sulfated 3,3',5-Triiodothyroacetic Acid

**TSH** : Thyroid Stimulating Hormone

**TSHR** : TSH Receptor

### Funding:

This work was supported in part by the Department of Veterans Affairs to S-y W and the National Institutes of Health (NIH) grants 1RO1 AR073298 and RO178843 to H-b Z, RO1 HL70562 and NIH R21 HD097498 to D-b C. The content is solely the responsibility of the authors and does not necessarily the official views of DVA and NIH.

**Disclosure:** None

### References

1. LaFranchi SH. (2014). Worldwide Coverage of Newborn Screening for Congenital Hypothyroidism - A Public Health Challenge in US Endocrinology. 10(2):115-116.
2. Leger J. (2015). Congenital hypothyroidism: a clinical update of long-term outcome in young adults. Eur J Endocrinol. 172: 67-77.
3. LaFranchi SH. (2021). Clinical features and detection of congenital hypothyroidism.
4. Sanchez AR, Guindulain MJC, Merillas MA, Segura SR, Nararro JCM, Arnao MDR. (2019). Diagnosis and follow-up of



- patients with congenital hypothyroidism detected by neonatal screening. *An Pediatr (Barc)*. 90(4):1-250.
5. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, O'Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, Faix JD, Klein RZ. (1999). Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. *N Engl J Med*. 341(8):549-555.
  6. Clairman H, Skocic J, Lischinsky JE, Rovet J. (2015). Do children with congenital hypothyroidism exhibit abnormal cortical morphology? *Pediatr Res*. 78(3):286-297.
  7. Bernal J. (2015). Thyroid hormone in brain development and function. Feingold KR, Anawalt B, Boyce A, et al. editors, *Endotext* [Internet], South Dartmouth: MDText.com.
  8. Forthead AJ, AL Fowden. (2014). Thyroid hormones in fetal growth and parturition maturation. *J Endocrinol*. 221:87-103.
  9. Morreale de Escobar G, Obregon MJ, Escobar del Rey F. (2004). Role of thyroid hormone during early brain development. *Eur J Endocrinol*. 151(S3):25-37.
  10. Wu SY, Green WL, Huang WS, Hays MT, Chopra IJ. (2005). Alternate pathways of thyroid hormone metabolism. *Thyroid*. 15(8):943-958.
  11. Wu, S. Y., W. L. Green. (2011). A 3,3'-diiodothyronine sulfate cross-reactive material (compound W), a potential marker for fetal hypothyroidism, In *Hypothyroidism Book II*, Intech Publisher, Rijeka, Croatia.
  12. Wu, SY, CH Emerson, E Tjioe, DB Chen. (2021). Maternal 3, 3'-diiodothyronine sulfate formation from guinea pig placenta perfused with 3,3',5-triiodothyronine, *J Endocrinol Disorder*. 5(6).
  13. Derakhshan A, Korevaar TIM, Taylor TN, Levie D, Guxens M, Jaddoe VDV, Nelson SM, Tiemeier H, Peeters RP. (2018). The association of maternal thyroid autoimmunity during pregnancy with child IQ. *J Clin Endocrinol Metab*. 103(10):3729-3736.
  14. Levie D, Korevaar TIM, Bath SC, Dalmau-Bueno A, Murcia M, Espada M, Dineva M, Ibarluzea JM, Tiemeier H, Rebagliato M, Rayman MP, Peeters RP, Guxens M. (2018). Thyroid function in early pregnancy, child IQ, and Autistic traits: a meta-analysis of individual participant data. *J Clin Endocrinol Metab*. 103(8):2967-2979.
  15. Vulsmat T, Gons MH, De vijlder JJ. (1989). Maternal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid dysgenesis. *N Engl J Med*. 321(1):13-16.
  16. Sulanc E. (2019). Mild-to-moderate iodine deficiency in early pregnancy is associated with lower verbal IQ in children. *Clinical Thyroidology for the Public*. 12(9):5-6.
  17. Mitchell, M.L., Klein, R.Z. (2004). The sequelae of untreated maternal hypothyroidism. *Eur J Endocrinol*. 151(S3):45-48.
  18. Leger J, Ecosse E, Roussey M, Lanoe JL, Larroque B, the French Hypothyroidism Study Group. (2011). Subtle health impairment and socioeducational attainment in young adult patients with congenital hypothyroidism diagnosed by neonatal screening: a longitudinal population-based cohort study. *J Clin Endocrinol Metab*. 96(6):1771-1782.
  19. Abel MH, Ystrom E, Caspersen IH, Meltzer HM, Aase H, Torheim LE, Askeland RB, Reichborn-Kjennerud T, Brantsaeter AL. Maternal iodine intake and offspring attention-deficit/hyperactivity disorder: results from a large prospective cohort study. *Nutrients*. 9(11):1239.
  20. Pearce EN. (2018). Higher preconception maternal iodine intakes are associated with higher child IQ. *Clin thyroidol*. 302-304.
  21. Harris KB, Pass KA. (2007). Increase in congenital hypothyroidism in New York State and in the United States. *Mol Genet Metab*. 91(3):268-277.
  22. Kurinczuk JJ, Bower C, Lewis B, Byrne G. (2002). Congenital hypothyroidism in Western Australia 1981-1998. *J Paediatr Child Health*. 38(2):187-191.
  23. Olivieri A, Fazzini C, Medda E. (2015). Italian Study Group for Congenital Hypothyroidism Multiple factors influencing the incidence of congenital hypothyroidism detected by neonatal screening. *Horm Res Paediatr*. 83(2):86-93.
  24. McGrath N, Hawkes CP, McDonnell CM, Cody D, O'Connell SM, Mayne PD, Murphy NP. (2018). Incidence of congenital hypothyroidism over 37 years of Ireland. *Pediatrics*. 142(4).
  25. Cherella CE, Wassner AJ. (2020). Update on congenital hypothyroidism. *Curr Opin Endocrinol Diabetes Obes*. 27(1):63-69.
  26. Panth P, Guerin G, DiMarco NM. (2019). A review of iodine status of women of reproductive age in the USA. *Biol Trace Elem Res*. 188(1):208-220.
  27. Burrow GN, Fisher DA, Larsen PR. (1994). Maternal and fetal thyroid function. *N Engl J Med*. 331(16):1072-1078.
  28. Polk DH, Reviczky A, Wu SY, Huang WS, Fisher DA. (1994). Metabolism of sulfoconjugated thyroid hormone in developing sheep. *Am J Physiol*. 266(6):892-896.
  29. Patel JK, Landers H, Li RH, Richard MR. (2011). Delivery of maternal thyroid hormones to the fetus. *Trends Endocrinol Metab*. 22(5):164-170.
  30. Wu, S. Y., D. H. Polk, E. Ho, D. A. Fisher. (2008). 3'-Monoiodothyronine sulfate and triac sulfate are thyroid hormone metabolites in developing sheep, *Pediatr Res* 63: 149-153.
  31. Wu SY, Huang TS, Polk D, Warner H, Green WL, Fisher DA. (1992). Identification of thyroxine-sulfate (T4S) in human serum and amniotic fluid by a novel T4S radioimmunoassay. *Thyroid*. 2(2):101-105.
  32. Wu SY, Polk D, Wong S, Reviczky A, Vu R, Fisher DA. (1992). Thyroxine Sulfate (T4S) is a major thyroid hormone metabolite and a potential intermediate in the monodeiodination pathways in fetal sheep. *Endocrinology*. 131(4):1751-1756.
  33. Wu SY, Huang WS, Polk D, Chen WL, Reviczky A, Chopra IJ, Fisher DA. (1992). The development of a radioimmunoassay for 3,3',5'-triiodothyronine sulfate (rT3S) in human serum and amniotic fluid. *J Clin Endocrinol Metab*. 75(1):189-194.
  34. Wu SY, Polk D, Fisher DA, Huang WS, Reviczky A, Chen WL. (1995). Identification of 3, 3' - T2S as a fetal thyroid hormone derivative in maternal urine in sheep. *Am J Physiol*. 268(1 Pt 1):33-39.
  35. Wu SY, Polk DH, Huang WS, Fisher DA. (1999). Fetal-to-maternal transfer of 3, 3', 5- triiodothyronine sulfate and its metabolite in sheep. *Am J Physiol*. 277(5):915-919.
  36. Chopra IJ. (2004). A radioimmunoassay for measurement of 3,3'-diiodothyronine sulfate: Studies in thyroidal and nonthyroidal diseases, pregnancy, and fetal/neonatal life. *Metabolism*. 53(4):538-543.
  37. Wu SY, Fisher DA. (2004). Measurement of 3,3'-diiodothyronine sulfate (T2S) in thyroidal and nonthyroidal disease, pregnancy, and fetal/neonatal life. *Metabolism*. 53(10):1388-1389.
  38. Chanoine J, Nève J, Wu SY, Vanderpas J, Bourdoux P. Selenium Decreases Thyroglobulin Concentrations But Does Not Affect the Increased Thyroxine-to-Triiodothyronine Ratio

- in Children with Congenital Hypothyroidism. *J Clin Endocrinol Metab.* 86(3):1160-1163.
39. Wu SY, Polk DH, Chen WL, Fisher DA, Huang WS, Yee B. (1994). A 3, 3' - diiodothyronine-sulfate cross-reactive compound in serum from pregnant women. *J Clin Endocrinol Metab.* 78(6):1505-1509.
  40. Huang WS, Roan CS, Kuo SW, Yan JS, Luo JS, Chen WL. (1995). Establishment of the sulfated 3,3'-diiodothyronine radioimmunoassay and its application in pregnant women. *Proc Natl Sci Counc Repub China B.* 19(4):201-207.
  41. Wu SY, Huang WS, Polk DH, Parker LN, Fisher DA, Galton VA. Sulfoconjugation is a major pathway of thyroid hormone metabolism in developing animals: from tadpoles to mammals. *Program 80th Annual Meeting of the Endocrine Society.* 248.
  42. Sack J, Beaudry M, DeLamater PV, Oh W, Fisher DA. (1976). Umbilical cord cutting triggers hypertriiodothyroninemia and non-shivering thermogenesis in the newborn lamb. *Pediatr Res.* 10(3):169.
  43. Santini F, Chiorato L, Ghirri P, Lapi P, Mammoli C, Montanelli L, Scartabelli G, Ceccarini G, Coccoli L, Chopra IJ, Boldrini A, Pinchera A. (1999). Serum iodothyronine in the human fetus and the newborn: evidence for an important role of placenta in fetal thyroid hormone homeostasis. *J Clin Endocrinol Metab.* 84(2):493-498.
  44. Wu SY, Polk DH, Huang WS, Green WL, Thai B, Fisher DA. (2006). Fetal-to-maternal transfer of thyroid hormone metabolites in late gestation in sheep. *Pediatr Res.* 59(1):102-106.
  45. Wu SY, Huang WS, Fisher DA, Florsheim WH, Kashiwai K, Polk DH. (2001). 3, 3'-diiodothyronine sulfate excretion in maternal urine reflects fetal thyroid function in sheep. *Pediatr Res.* 50(3):358-364.
  46. Moreno M, Lanni A, Lombardi A, Goglia F. (1997). How the thyroid controls metabolism in the rat: different roles for triiodothyronine and diiodothyronines. *J Physiol.* 505(2): 529-538.
  47. Senese, R, Cioffi F, Petito G, Goglia F, Lanni A. (2019). Thyroid hormone metabolites and analogues. *Endocrine.* 66(1):105-114.
  48. Chen D, Yu H, Bao J, Xue W, Xing Y, Zhang L, Green WL, Fisher DA, Wu SY. (2012). 3, 3'-Diiodothyronine sulfate cross-reactive material (Compound W) in human newborns. *Pediatr Res.* 72(5):521-524.
  49. Wu SY, Huang WS, Ho E, Wu ESC, Fisher DA. (2007). A 3,3'-diiodothyronine sulfate cross-reactive substance, compound W, in serum from pregnant women – a potential marker for fetal thyroid function. *Pediatr Res.* 61(3):307-312.
  50. Wu SY, Ma C, Xi BX, Synold T. (2018). A fresh look at W-compound: a potential marker for fetal thyroid function. *Pediatric Dimensions.* 3(1):2-6.
  51. Cortelazzi D, Morpurgo PS, Zamperini P, Fisher DA, Beck-Peccoz P, Wu SY. (1999). Maternal compound W serial measurement for management of fetal hypothyroidism, *Europ J Endocrinol.* 141:570-578.
  52. Huang B, Yu BX, Bao JD, Zhang MD, Green WL, Wu SY. (2018). A homogeneous time-resolved fluorescence immunoassay method for the measurement of compound W. *Biomarker Insight.* 13:1-6.
  53. Leonetti CP, Butt CM, Stapleton HM. (2018). Disruption of thyroid hormone sulfotransferase activity by brominated flame retardant chemicals in the human chorionic carcinoma placenta cell line BeWo. *Chemosphere.* 197:81-88.
  54. Wang D, Stapleton HM. (2010). Analysis of thyroid hormone in serum by Liquid Chromatography-Tandem Mass Spectrometry. *Analy Bioanal Chem.* 397(5):1831-1839.
  55. Butt CM, Stapleton HM. (2013). Inhibition of thyroid hormone sulfotransferase activity by brominated flame retardants and halogenated phenolics. *Chem Res Toxicol.* 26(11):1692-1702.
  56. Wu SY, Chopra IJ, Nakamura Y, Solomon GH, Bennett LR. (1976). A radioimmunoassay for measurement of 3,3'-L-diiodothyronine (T2). *J Clin Endocrinol Metab.* 43(3):682-685.



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here:

[Submit Manuscript](#)

DOI: [10.31579/2640-1045/122](https://doi.org/10.31579/2640-1045/122)

#### Ready to submit your research? Choose Auctores and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At Auctores, research is always in progress.

Learn more <https://auctoresonline.org/journals/endocrinology-and-disorders>